Tirzepatide Investigated for Plasma Volume Reduction in Obesity-Related Heart Failure with Preserved Ejection Fraction
Background
Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge, particularly in patients with obesity. Current treatments often struggle to address the complex interplay of metabolic dysfunction, inflammation, and fluid overload that characterizes obesity-related HFpEF. Incretin-based therapies like tirzepatide, a dual GLP-1R and GIPR agonist, have shown significant benefits in weight loss and metabolic parameters, leading to the hypothesis that they might also improve cardiac function by reducing plasma volume and adipokine-mediated inflammation. This trial seeks to elucidate these specific mechanisms.
Study Design
This Phase 4 clinical trial (NCT07554638) will enroll an estimated 50 participants with obesity and heart failure with preserved ejection fraction (HFpEF). Participants will be prescribed tirzepatide (dose not specified) to investigate its effect on plasma volume. The study aims to measure reductions in plasma volume, alongside body composition analysis and adipokine levels, to identify therapeutic mechanisms. This Columbia University-sponsored trial is NOT_YET_RECRUITING, with an estimated start in June 2026 and completion in April 2030.
Results
As this is a protocol for a NOT_YET_RECRUITING Phase 4 clinical trial (NCT07554638), no actual results or findings are available at this time. The study's central aim is to test a specific hypothesis:
Patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. This investigation seeks to identify the therapeutic mechanisms underlying incretin-based treatment in this complex patient population. Researchers plan to analyze changes in plasma volume, alongside
state-of-the-art body composition analysisandadipokinemeasurements. The trial, sponsored by Columbia University, is estimated to enroll 50 participants, with data collection projected from June 2026 to April 2030. Specific outcomes and statistical significance will be reported upon trial completion.
Key Findings
- Tirzepatide hypothesized to reduce plasma volume in obesity-related HFpEF.
- Trial to investigate therapeutic mechanisms of incretin-based treatment in HFpEF.
- Study will analyze body composition and adipokine levels alongside plasma volume.
- Phase 4 trial (NCT07554638) is
NOT_YET_RECRUITINGwith an estimated N=50.
Why It Matters
If successful, this trial could establish tirzepatide as a targeted therapy for obesity-related HFpEF, offering a novel approach beyond current symptomatic management. For clinicians, it would provide evidence for using GLP-1R/GIPR agonists to directly address cardiac dysfunction in this specific patient population. Peptide users interested in metabolic health and cardiovascular benefits might see this as further validation of incretin mimetics' broad therapeutic potential. The focus on plasma volume reduction and adipokine modulation highlights a mechanistic understanding that could inform future combination therapies or personalized treatment strategies for complex cardiometabolic conditions.
tirzepatide
hfpef
obesity
heart failure
clinical trial
phase 4